First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac

DSpace/Manakin Repository

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac
 
On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium
(2022) Technical Innovations and Patient Support in Radiation Oncology, volume 22, pp. 50 - 54
(Article)
Abstract
The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: (3–6): oligometastases, MOMENTUM, MR-guided radiotherapy, MR-Linac, SABR, Care Planning, Oncology(nursing), Health Policy, Radiology Nuclear Medicine and imaging, Journal Article
DOI: https://doi.org/10.1016/j.tipsro.2022.04.005
ISSN: 2405-6324
Publisher: Elsevier Ireland Ltd
Note: Funding Information: K. Aitken reports institutional funding from the NIHR as a Biomedical Research Centre and institutional funding from Elekta to support their MR-linac research program including clinical research fellow funding. Funding Information: T.M. Janssen, and M.E. Nowee, P. S. Kroon, I. M. Jürgenliemk-Schulz, H.M. Verkooijen, U. Bernchou report (institutional) research funding from Elekta. Funding Information: W.A. Hall and H. Saeed report Institutional research support from Elekta AB, Stockholm, Sweden, W.A. Hall is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number KL2TR001438. The content is solely the responsibility of the author(s) and does not necessarily represent the official views of the NIH. Funding Information: S. Boeke and M. Nachbar report that he MRgRT program in Tübingen received funding from the German Research Council (ZI736/2-1). The Department of Radiation Oncology Tübingen receives within the frame of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta AB (Stockholm, Sweden), Kaiku Health (Helsinki, Finland) TheraPanacea (Paris, France), Philips GmbH (Best, The Netherlands); Dr. Sennewald Medizintechnik GmbH (München, Germany), PTW Freiburg (Germany). Publisher Copyright: © 2022 The Author(s)
(Peer reviewed)